TB-500 Side Effects: Safety Signals and Warnings
TB-500 safety concerns are compound-specific. The main listed side effects are Generally well-tolerated in clinical trials at doses up to 6 mg (RegeneRx Phase 2 data), Head rush or transient lightheadedness immediately post-injection (anecdotally reported, not systematically documented in trials), and Mild injection site reactions (erythema, induration) at higher doses. The main warning signals are Not FDA-approved for any indication, Banned by WADA under the category of peptide hormones, growth factors, and related substances - prohibited for all competitive athletes, and Theoretical concern: as a pro-angiogenic, pro-migratory peptide, Tβ4 could theoretically support tumor growth or metastasis - this risk has not been observed in clinical trials but has not been definitively excluded in long-term use.
Direct Answer
TB-500 has a critical advantage over most healing peptides: its mechanism (G-actin sequestration) has been independently replicated by multiple research groups, and RegeneRx conducted formal Phase 2 human trials. Those trials produced mixed results - positive trends but not statistical significance on primary endpoints. The translational gap likely reflects formulation and dosing challenges, not a false preclinical signal. For musculoskeletal research, TB-500 is the best-evidenced starting point that also has independent mechanistic validation.
- Evidence grade
- Level B
- Research status
- Phase 2
- Category
- Healing & Recovery
- Best for
- Musculoskeletal repair, wound healing, cardiac recovery
Reported Side Effects
- Generally well-tolerated in clinical trials at doses up to 6 mg (RegeneRx Phase 2 data)
- Head rush or transient lightheadedness immediately post-injection (anecdotally reported, not systematically documented in trials)
- Mild injection site reactions (erythema, induration) at higher doses
- Transient lethargy in some users (anecdotal; not a documented finding in clinical trials)
Warnings
- Not FDA-approved for any indication
- Banned by WADA under the category of peptide hormones, growth factors, and related substances - prohibited for all competitive athletes
- Theoretical concern: as a pro-angiogenic, pro-migratory peptide, Tβ4 could theoretically support tumor growth or metastasis - this risk has not been observed in clinical trials but has not been definitively excluded in long-term use
- Limited long-term human safety data (longest published trial approximately 6 months)
Known or Plausible Interactions
- Anticoagulants (Tβ4's pro-angiogenic activity may theoretically affect wound vascularization in anticoagulated patients)
- Immunosuppressants (potential interaction via shared NF-κB pathway modulation)
- Other growth-promoting peptides (additive effects not studied)
Regulatory Context
TB-500 (synthetic thymosin beta-4) is not FDA-approved for any therapeutic use and cannot be legally marketed for human consumption in the United States. It is a research chemical. WADA prohibits Tβ4 under the Growth Factors and Related Substances section (S2) - athletes in tested sports should treat TB-500 as prohibited. Regulatory status varies internationally.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Wound Healing (Level B), Cardiac Repair (Level B), Anti-Inflammation (Level B), and Dry Eye / Corneal Healing (Level B) |
| Primary citation count | 6 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "TB-500 Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tb-500-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.